title: Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events.
authors.forename: Paul E
authors.initials: PE
authors.lastname: Langton
authors.forename: Graeme J
authors.initials: GJ
authors.lastname: Hankey
authors.forename: John W
authors.initials: JW
authors.lastname: Eikelboom
mesh_terms: D002318:Cardiovascular Diseases / Q000139:chemically induced*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D011358:Product Surveillance, Postmarketing; D018570:Risk Assessment; D013450:Sulfones / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib